Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma

Authors: Chih-Ming Ho, Chi-Jung Huang, Chia-Yen Huang, Yih-Yiing Wu, Shwu-Fen Chang, Wen-Fang Cheng

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

This study is to analyze promoter methylation of various tumor suppressor genes in different types of ovarian carcinoma and to identify potential therapeutic targets of ovarian clear cell adenocarcinoma (OCCA).

Materials and methods

The promoter methylation statuses of 40 genes in primary ovarian carcinomas including 47 clear- and 63 non-clear-cell type tissues, 6 OCCA cell lines, 29 benign ovarian endometriotic cysts, and 31 normal controls were analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). The MS-MLPA results were correlated with clinicopathological features and outcomes of 47 OCCA patients. Functions of the target genes were further explored by Western Blot Analysis, apoptosis assay, and caspase-3/7 activity analysis.

Results

Frequencies of methylated RASSF1A, CDH13, CACNA1A, HIN-1, and sFRP5 genes in OCCA tissues were significantly higher than those in non-OCCA cancerous tissues and benign endometriotic cysts. The expected OS for patients with methylated promoters of HIN-1 was significantly worse than those for patients without methylated HIN-1 (30% vs. 62%, p = 0.002). The HIN-1 gene was over-expressed in ES2 cells, a significant reduction in cell growth and induction of apoptosis, and increasing paclitaxel sensitivity by reducing phosphorylation of Akt were observed.

Conclusions

Methylation of HIN-1 promoter is a novel epigenetic biomarker associated with poor outcomes in OCCA patients. Ectopic expression of the HIN-1 gene increased paclitaxel sensitivity which is partly through Akt pathway.
Appendix
Available only for authorised users
Literature
1.
Serov SF, Scully RE, Robin IH: International histological classification of tumors: no. 9. histological typing of ovarian tumours. 1973, 37-42. Geneva: World Health Organization.
2.
Kennedy AW, Biscotti CV, Hart WR, Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989, 32: 342-349. 10.1016/0090-8258(89)90637-9CrossRefPubMed
3.
Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxelplatinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004, 94: 197-203. 10.1016/j.ygyno.2004.04.004CrossRefPubMed
4.
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histological type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5CrossRefPubMed
5.
Ho CM, Chien TY, Shih BY, Huang SH: Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol. 2003, 88: 394-399. 10.1016/S0090-8258(02)00156-7CrossRefPubMed
6.
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003, 163: 2503-2512. 10.1016/S0002-9440(10)63605-XPubMedCentralCrossRefPubMed
7.
Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S: Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer. 1999, 85: 669-677. 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-FCrossRefPubMed
8.
Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer. 2005, 104: 1924-1930. 10.1002/cncr.21397CrossRefPubMed
9.
Ho CM, Lai HC, Huang SH, Chien TY, Lin MC, Chang SF: Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest. 2010, 40: 310-318. 10.1111/j.1365-2362.2010.02266.xCrossRefPubMed
10.
Ho CM, Lin MC, Huang SH, Huang CJ, Lai HC, Chien TY, Chang SF: PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol. 2009, 112: 307-313. 10.1016/j.ygyno.2008.09.040CrossRefPubMed
11.
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IM: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009, 174: 1597-1601. 10.2353/ajpath.2009.081000PubMedCentralCrossRefPubMed
12.
Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IM, Wang TL: DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010, 16: 1997-2008. 10.1158/1078-0432.CCR-09-2105PubMedCentralCrossRefPubMed
13.
Jones S, Wang TL, Shih IeM Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N: Mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010, 330: 228-231. 10.1126/science.1196333PubMedCentralCrossRefPubMed
14.
Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000, 24: 132-138. 10.1038/72785CrossRefPubMed
15.
Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003, 3: 253-266. 10.1038/nrc1045CrossRefPubMed
16.
Esteller M: CpG island hypermethylation and tumor suppressor genes: booming present, a brighter future. Oncogene. 2002, 21: 5427-5240. 10.1038/sj.onc.1205600CrossRefPubMed
17.
Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9CrossRefPubMed
18.
Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 2009, 100: 1144-1153. 10.1038/sj.bjc.6604964PubMedCentralCrossRefPubMed
19.
Scott RH, Douglas J, Baskcomb L, Nygren AO, Birch JM, Cole TR, Cormier-Daire V, Eastwood DM, Garcia-Minaur S, Lupunzina P, Tatton-Brown K, Bliek J, Maher ER, Rahman N: Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet. 2008, 45: 106-113.CrossRefPubMed
20.
Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, Sánchez-Carbayo M: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010, 8: 86-96. 10.1186/1479-5876-8-86PubMedCentralCrossRefPubMed
21.
Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP: Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch. Otolaryngol Head Neck Surg. 2006, 132: 668-677. 10.1001/archotol.132.6.668CrossRefPubMed
22.
Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E, van Diest PJ: Methylation profiles of hereditary and sporadic ovarian cancer. Histopathol. 2010, 57: 363-370. 10.1111/j.1365-2559.2010.03642.x. 10.1111/j.1365-2559.2010.03642.xCrossRef
23.
Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007, 6: 45-54. 10.1186/1476-4598-6-45PubMedCentralCrossRefPubMed
24.
Yoon MS, Suh DS, Choi KU, Sol MY, Shin DH, Park WY, Lee JH, Jeong SM, Kim WG, Shin NR: High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. Oncol Rep. 2010, 24: 917-925.PubMed
25.
Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW: DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One. 2010, 5: e9359-e9374. 10.1371/journal.pone.0009359PubMedCentralCrossRefPubMed
26.
27.
Wong TS, Kwong DL, Sham JS, Tsao SW, Wei WI, Kwong YL, Yuen AP: Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. Clin Cancer Res. 2003, 9: 3042-3046.PubMed
28.
Marchetti A, Barassi F, Martella C, Chella A, Salvatore S, Castrataro A, Mucilli F, Sacco R, Buttitta F: Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res. 2004, 10: 1338-1343. 10.1158/1078-0432.CCR-1174-03CrossRefPubMed
29.
Shigematsu H, Suzuki M, Takahashi T, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF: Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer. 2005, 113: 600-604. 10.1002/ijc.20622CrossRefPubMed
30.
Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K: Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004, 2: 489-494.PubMed
31.
Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K: HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation. Cancer Res. 2005, 65: 9659-9669. 10.1158/0008-5472.CAN-05-1663CrossRefPubMed
32.
Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR: Stage-Specific Alterations of DNA Methyltransferase Expression, DNA Hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res. 2008, 6: 1365-1374. 10.1158/1541-7786.MCR-08-0040PubMedCentralCrossRefPubMed
33.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD, Australian Ovarian Cancer Study Group: IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011, 17: 2538-2548. 10.1158/1078-0432.CCR-10-3314CrossRefPubMed
34.
Wang V, Davis DA, Haque M, Huang E, Yarchoan R: Differential gene up-regulation by Hypoxia-Inducible Factor-1A and Hypoxia-Inducible Factor-2A in HEK293T Cells. Cancer Res. 2005, 65: 3299-3306.PubMed
35.
Mazumdar J, Hickey MM, Pant DP, Durham AC: HIF-2α deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA. 2010, 107: 14182-14187. 10.1073/pnas.1001296107PubMedCentralCrossRefPubMed
Metadata
Title
Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma
Authors
Chih-Ming Ho
Chi-Jung Huang
Chia-Yen Huang
Yih-Yiing Wu
Shwu-Fen Chang
Wen-Fang Cheng
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-53

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Short communication

IRF5 promotes the proliferation of human thyroid cancer cells

Research

Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system

Research

Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model

Research

Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection

Short communication

Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1

Research

β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits